Ranked papers
#1
Sukumar JS, Raghavendra AS, Pasyar S, et al. · Cancer Res Commun · 2026
What it measured: Weight and clinical outcomes in breast cancer survivors who started the drug
The most directly relevant dataset published: a cancer-center cohort of 1,022 survivors of nonmetastatic breast cancer who took a GLP-1 drug between 2005 and 2024, 79% of them with type 2 diabetes. Among the 442 on semaglutide or tirzepatide, median weight change was only −1.9% at three months, −3.1% at six and −2.6% at a year, far below what the registration trials report, and endocrine therapy was linked to weight gain. Against matched nonusers, GLP-1 users had better overall survival (hazard ratio 0.37) but no difference in disease-free survival. It is observational, with no placebo group.
PMID 41677473 ↗DOI 10.1158/2767-9764.CRC-25-0554 ↗
#2
Cornelio CK, Cowart K, Perkins J, et al. · Pharmacotherapy · 2026
What it measured: Cardiac events among women carrying breast cancer alongside type 2 diabetes
The first cardiovascular outcomes analysis limited to women who have type 2 diabetes as well as breast cancer, comparing those who started a GLP-1 against those started on other diabetes drugs in a large claims dataset. Fewer cardiovascular events on the GLP-1, consistent with what the big trials show in the general population. Confounding by indication is the live problem here, and cancer stage, which drives both prognosis and prescribing, was incompletely captured. It is a bridge to a trial, not a substitute for one.
PMID 41801847 ↗DOI 10.1002/phar.70130 ↗
#3
Wooster M, Chen L, Accordino MK, et al. · Breast Cancer Res Treat · 2025
What it measured: Cardiovascular event incidence by weight-management treatment utilization
An examination of who receives weight-management treatment after breast cancer (drugs, surgery or behavioral programs) and what happens to their cardiovascular risk afterward. Its limitation is a matter of timing: the data end in 2021, before access to these drugs widened sharply, so the treatment mix it describes is already historical. It is most useful for the disparity question, which is who gets offered anything at all.
PMID 40360855 ↗DOI 10.1007/s10549-025-07714-6 ↗
#4
Lopez DS, Abdelgadir O, Zhang Y, et al. · Obesity (Silver Spring) · 2026
What it measured: Heart disease rates by whether women took a weight drug and had prior cancer
A SEER-Medicare study of 46,552 women aged 65 and over, half of them survivors of an obesity-related cancer and half matched cancer-free women, drawn from 2007 to 2015, when the modern drugs barely existed. Use of the older weight-loss drugs was associated with less heart disease overall (hazard ratio 0.80). Among survivors, the association pointed the same way but reached significance only in the per-protocol analysis (0.74). Read it as a baseline from the pre-GLP-1 era rather than as evidence about GLP-1s, which the authors say need their own studies.
PMID 42083112 ↗DOI 10.1002/oby.70211 ↗
#5
Jung W, Park SH, Park YM, et al. · Breast Cancer Res Treat · 2025
What it measured: Heart disease rates by how much weight changed after a cancer diagnosis
The strongest population-level evidence here, and it tests no drug at all. Using Korean national insurance data on 42,547 survivors, it tracked how weight change after a breast cancer diagnosis relates to later heart attack and stroke. Gaining more than 10% raised the risk (adjusted hazard ratio 1.66) against keeping weight stable, and sustained obesity carried more risk in survivors under 50 and in those on tamoxifen. It shows the cost of weight gain. Whether deliberate weight loss lowers the risk is what the authors say intervention studies, such as GLP-1 trials, now need to test.
PMID 39762706 ↗DOI 10.1007/s10549-024-07594-2 ↗
#6
Howard R, Pilewskie M, Dossett LA · JAMA Oncol · 2026
What it measured: Narrative synthesis
An editorial arguing that oncology has been slow to bring effective obesity treatment into cancer care across prevention, treatment and survivorship, and setting out the trials, guidelines and coverage barriers standing in the way. It contains no new data, and it is a short Viewpoint focused on how rarely survivors are offered GLP-1 drugs or bariatric surgery.
PMID 41954902 ↗DOI 10.1001/jamaoncol.2026.0260 ↗
#7
Hundal J, Chen J, Russell KB, et al. · Am Soc Clin Oncol Educ Book · 2026
What it measured: Narrative review
A survivorship-curriculum chapter integrating lifestyle, weight management and psychological care after breast cancer, and one of the first mainstream oncology-education sources to name these drugs as a survivorship tool rather than strictly an obesity-medicine one. Educational positioning is not a guideline endorsement, and the chapter stops deliberately short of one. If a survivor asks whether their oncology society backs this use, this is the accurate answer to give them.
PMID 42127339 ↗DOI 10.1200/EDBK-26-517396 ↗
#8
Fore-Williams L, Distler M · J Adv Pract Oncol · 2026
What it measured: Narrative review
The only review focused on tamoxifen-associated weight gain specifically, a problem affecting a large share of premenopausal survivors across five to ten years of therapy and one rarely addressed on its own. It covers lifestyle and drug options, and how the moment you intervene interacts with endocrine therapy still in progress. Its most valuable feature is candor: it states outright that no randomized data exists in this exact population, and offers a practical approach anyway.
PMID 42170166 ↗DOI 10.6004/jadpro.2026.17.3.3 ↗
#9
Pahulu I, Calumpit M, Tominez P, et al. · JNCI Cancer Spectr · 2026
What it measured: Systematic review
A systematic review of diet, nutrition and hormone therapy in prostate cancer, and the closest published synthesis of the androgen-deprivation weight problem. That therapy reliably drives visceral fat gain, muscle loss, insulin resistance and elevated cardiovascular mortality, a combination that plausibly responds differently to these drugs than ordinary obesity does. The authors map what has been tried, note that no dedicated randomized trial exists in men on this therapy, and call for one. That call is the paper's contribution.
PMID 41703670 ↗DOI 10.1093/jncics/pkag014 ↗
#10
Kajitani N, Takahashi J, Honda H, et al. · Intern Med · 2020
What it measured: Case description
A single case report, included as illustration rather than evidence: a 79-year-old man who developed severe visceral obesity, fatty liver and new type 2 diabetes within eight months of surgical removal of the testes for prostate cancer. Treatment with canagliflozin and the GLP-1 drug dulaglutide improved his blood sugar, visceral fat and fatty liver, and the authors suggest that combination may help after this surgery. It is one patient, and the authors note his visceral-fat pattern differed from the usual course after androgen deprivation, but it shows the metabolic problem this whole question is about.
PMID 32522924 ↗DOI 10.2169/internalmedicine.4653-20 ↗
About this list
Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-10-30 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.
Browse our full index of research lists or our long-form research articles.